Fri, 30th Apr 2021 07:10
April 30 (Reuters) - AstraZeneca said on Friday it
expected higher sales in the second half of the year, as it
reported first-quarter profit and sales ahead of analysts'
average expectations, including $275 million in COVID-19 vaccine
sales.
(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger
in Frankfurt; editing by John Stonestreet)
(Alliance News) - Stock prices in London got a boost at midday on Monday, as investors eye a key UK inflation reading later in the week, which is expe...
(Alliance News) - AstraZeneca PLC on Monday announced plans for a USD1.5 billion manufacturing facility in Singapore to produce antibody drug conjugat...
(Alliance News) - London's FTSE 100 is called to open higher at the start of the week, while the pound climbed and gold hit another record high, with ...
(Sharecast News) - AstraZeneca announced plans to construct a $1.5bn manufacturing facility in Singapore on Monday, dedicated to the production of ant...
(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.
Astrazeneca (AZN)